Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means

Moderna and Merck have achieved a historic milestone with the first mRNA cancer vaccine to successfully complete a Phase 3 trial. This breakthrough, which outperformed the standard of care, triggered a massive surge in Moderna stock, with shares increasing by 131%. The positive clinical results had a significant impact on the financial market, resulting in losses of approximately $4.8 billion for short sellers as investors reacted to the successful development of the new vaccine.